

| Clinical Policy Title: | abiraterone |
|-------------------------------------|---|
| Policy Number: | RxA.325 |
| Drug(s) Applied: | Zytiga®, Yonsa®, abiraterone |
| Original Policy Date: | 02/07/2020 |
| Last Review Date: | 2/1/2024 |
| Line of Business Policy Applies to: | All lines of business (except Medicare) |

Criteria

I. Initial Approval Criteria

- A. Castration resistant (chemical or surgical) prostate cancer (CRPC) (must meet all):
 - 1. Diagnosis of CRPC;
 - 2. Zytiga and Yonsa requests only:
 - a. Trial and failure, contraindication, or intolerance to Xtandi;

Approval duration:

All Lines of Business (except Medicare): 6 months

- **B.** Diagnosis of castration-sensitive prostate cancer (CSPC) (must meet all):
 - 1. Diagnosis of CSPC
 - 2. Zytiga requests only:
 - a. Trial and failure, contraindication, or intolerance to Erleada or Xtandi

Approval duration:

All Lines of Business (except Medicare): 6 months

II. Continued Therapy Approval

- A. Prostate Cancer (must meet all):
 - 1. Member is currently receiving or has been treated with this medication within the past 90 days, excluding manufacturer samples.

Approval duration

All Lines of Business (except Medicare): 12 months

References

1. National Comprehensive Cancer Network. Prostate Cancer Version 01.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed April 17, 2023.

| Review/Revision History | Review/Revision Date | P&T Approval Date |
|---|----------------------|-------------------|
| Policy established. | 01/2020 | 02/07/2020 |
| Policy was reviewed: 1. Policy title was updated. | 07/28/2020 | 09/14/2020 |

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

^{*}Diagnosis not approved for Yonsa



| runs on Collaborative PBM Cloud ™ | | |
|--|------------|------------|
| Indications were updated. Initial Approval criteria updated. Continued Therapy Approval criteria II.A.1 was rephrased. References were updated. | | |
| Policy was reviewed: 1. Initial and Continued therapy criteria approval duration was updated to remove HIM approval duration. 2. Continued Therapy criteria II.A.1 was rephrased to "Member is currently receiving medication that has been authorized by RxAdvance". 3. References were reviewed and updated. | 05/31/2021 | 09/14/2021 |
| Policy was reviewed: Initial Approval Criteria I.A.5.a was updated to include "Can use dexamethasone 1 mg/day in place of prednisone". Initial Approval Criteria I.A.6.a.i was updated to include "Can use dexamethasone 1 mg/day in place of methylprednisolone". Initial Approval Criteria and Continued Therapy Approval Criteria were updated to remove HIM approval duration. References were reviewed and updated. | 6/4/2021 | 09/14/2021 |
| Policy was reviewed: 1. Initial Approval Criteria, I.A.5: Updated combination therapy criteria from For Zytiga® requests: prescribed in combination with prednisone a. Can use dexamethasone 1 mg/day in place of prednisone to For Zytiga® requests: prescribed in combination with prednisone (Can use dexamethasone 1 mg/day in place of prednisone (Can use dexamethasone 1 mg/day in place of prednisone. 2. Initial Approval Criteria, I.A.6.a.: Updated combination therapy criteria from For Yonsa® requests, both of the following (a and b): | 3/16/2022 | 07/18/2022 |

^{© 2023} RxAdvance Corporation. All rights reserved. This policy contains the confidential and proprietary information of RxAdvance. Unauthorized reproduction, distribution, modification, display, storage, transmission, or use of this policy or any information contained herein is strictly prohibited.

Revised 10/2023 Page 2 of 3 v 2.0.01.1



| a. Prescribed in combination with methylprednisolone i. Can use dexamethasone 1 mg/day in place of methylprednisolone); to For Yonsa® requests, both of the following (a and b): a. Prescribed in combination with methylprednisolone (Can use dexamethasone 1 mg/day in place of methylprednisolone); 3. References reviewed and updated. | | |
|---|------------|------------|
| Policy was reviewed: 1. Initial Approval Criteria I.A.4: Updated to remove requirements for history of bilateral orchiectomy, previously filled androgen deprivation therapy (ADT) and using ADT concurrently. 2. Initial Approval Criteria I.A.4: Updated to add that Member will use a gonadotropin-releasing hormone (GnRH) analog concurrently or has had a bilateral orchiectomy. 3. References reviewed and updated. | 04/21/2023 | 7/13/2023 |
| Policy was reviewed. | 10/19/2023 | 10/19/2023 |
| Policy update: 1. Reflect 1/1 changes 2. Remove dosing, prescriber | 1/1/2024 | 1/1/2024 |

Revised 10/2023 Page 3 of 3 v 2.0.01.1